Clinical Study on Efficacy and Treg Cell Changes in Peripheral Blood of Massive Liver Cancer Treated with Gelfoam Microparticles (GSMs) TACE Combined with Surgical Resection

Abstract

Objective: Observe the clinical efficacy and safety of using absorbable GSMs embolization agent to embolize massive liver cancer, and to observe the changes in the changes of Treg cells in peripheral blood. Methods: During 2018-2019 GSMs-TACE combined with conventional resection of liver cancer treatment of 7 cases of massive liver cancer. GSMs particle of 150-350, mixed with 50 mg doxorubicin, 30 days later underwent conventional surgery. Flow cytometry is used to test the content of Treg cells in peripheral blood before , 10 days after GSMs-TACE and before conventional surgical. Results: The average resection month after GSMs-TACE (14-48 days) was one month in 7 patients, and the volume of tumor necrosis after GSMs-TACE was more than 50%, among which 5 cases were more than 90%. After embolization, the tumor volume decreased by 20.2%, and the right hemihepatic resection was performed in 6 cases and the middle hepatic resection was performed in 1 case. There were no sever complications. The survival rates at 6 months and 12 months after resection were 100% (7/7) and 100% (5/5). The Treg cells in peripheral blood was 11.72 ±0.91%, 8.62 ±1.43%, and 10.34 ±1.12%, before, 10 days and 30 days after GSMs-TACE. Conclusions: GSMs-TACE combined with surgical resection in the treatment of massive liver cancer has a good safety and clinical efficacy, GSMs-TACE has a positive regulatory effect on the body´s immune function.GSMs-TACE 15 to 30 days after surgery is the best time for surgical resection.